



8th June 2016

Re: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia (SPIRIT 2)

Dear SPIRIT 2 Participant,

We are writing to all patients participating in the SPIRIT 2 trial who are taking dasatinib. Although dasatinib is a very successful drug in treating chronic myeloid leukaemia, approximately one quarter of patients taking dasatinib can develop shortness of breath. One reason for this is fluid developing around the lungs. This is known as pleural effusion.

Pleural effusion caused by dasatinib is usually easily treated by a change in dasatinib dose. If you do become breathless, either at rest or during minimal exercise, like walking upstairs, please contact your Haematologist. As a precaution, your Haematologist may decide to stop your dasatinib. While your dasatinib is interrupted your CML will continue to be closely monitored. Once your symptoms have improved, your Haematologist may reintroduce dasatinib at a lower dose and, if necessary, increase the dose slowly to maintain good control of your CML.

We have enclosed a Patient Alert Card, which you can keep in your purse or wallet. The Patient Alert Card has space for the name of your Haematologist and research nurse as well as a contact number should you need to contact them.

Thank you for continuing to be a part of SPIRIT 2.

Kind regards,

The **SPIRIT 2** Trial Team